New drug combo aims to slow ALS in landmark trial
Disease control
Recruiting now
This Phase 2 trial is testing an investigational drug called COYA 302 in 120 adults with ALS. The drug combines two immune-modulating agents to reduce inflammation that may damage nerves. Participants will receive either COYA 302 or a placebo for 24 weeks, with an option to conti…
Phase: PHASE2 • Sponsor: Coya Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC